Мятежная клетка. Рак, эволюция и новая наука о жизни

Fojo, T., Mailankody, S. and Lo, A. (2014) Unintended consequences of expensive cancer therapeutics – the pursuit of marginal indications and a Me-Too mentality that stifles innovation and creativity: The John Conley Lecture, JAMA Otolaryngol Head Neck Surg. 140:1225–1236 doi:10.1001/ jamaoto.2014.1570

Lomangino, K. (2017) 'Not statistically significant but clinically meaningful': A researcher calls 'BS' on cancer drug spin, Health News Review (published online 24 March 2017) bit.ly/35riDTq

Oyedele, A. (2014) 19 of the Most Expensive Substances In the World, Business Insider (published online 22 September 2014) bit.ly/36kqx1W

Kim, C. and Prasad, V. (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals, JAMA Intern Med. 175: 1992–4 doi:10.1001/jamainternmed.2015.5868

Prasad, V., McCabe, C. and Mailankody, S. (2018) Low-value approvals and high prices might incentivize ineffective drug development, Nat Rev Clin Oncol 15: 399–400 doi:10.1038/ s41571–018–0030–2

Prasad, V. and Mailankody, S. (2017) Research and development spending to bring a single cancer drug to market and revenues after approval, JAMA Intern Med. 177: 1569–1575 doi:10.1001/jamainternmed.2017.3601

Prasad, V. (2016) Perspective: The precision-oncology illusion, Nature 537: S63 doi:10.1038/537S63a

Perelson, A.S., Neumann, A.U., Markowitz, M. et al (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time, Science 271: 1582–6 doi:10.1126/science.271.5255.1582

The Antiretroviral Therapy Cohort Collaboration (2017) Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies, The Lancet HIV 4: PE349-E356 doi:10.1016/ S2352–3018(17)30066–8

Clarke, P.A., Roe, T., Swabey, K. et al. (2019) Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer, Oncogene 38: 5076–5090 doi:10.1038/s41388–019–0780-z

Behan, F.M., Iorio, F., Picco, G. et al. (2019) Prioritization of cancer therapeutic targets using CRISPR – Cas9 screens, Nature 568: 511–516 doi:10.1038/s41586–019–1103–9

Momen, S., Fassihi, H., Davies, H.R. et al. (2019) Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease, Cold Spring Harb Mol Case Stud 5: a004408 doi:10.1101/mcs.a004408

ГЛАВА 10

Markus, C. and McFeely, S. (2018) Avengers: Infinity War, dir. Russo, A. and Russo, J. Marvel Studios

Enriquez-Navas, P.M., Wojtkowiak, J.W. and Gatenby, R.A. (2015) Application of evolutionary principles to cancer therapy, Cancer Res. 75: 4675–80 doi:10.1158/0008–5472. CAN-15–1337

Enriquez-Navas, P.M., Kam, Y., Das, T. et al. (2016) Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer, Science Translational Medicine 8: 327ra24 doi:10.1126/scitranslmed.aad7842

Wang, L. & Bernards, R. (2018) Taking advantage of drug resistance, a new approach in the war on cancer, Front. Med. 12: 490 doi:10.1007/s11684–018–0647–7

Gatenby, R.A., Silva, A.S., Gillies, R.J. and Frieden, B.R. (2009) Adaptive therapy, Cancer Res. 69: 4894–903 doi:10.1158/0008–5472.CAN-08–3658

Zhang, J., Cunningham, J.J., Brown, J.S., and Gatenby, R.A. (2017) Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer, Nat Commun. 8: 1816 doi:10.1038/s41467–017–01968–5

Khan, K.H., Cunningham, D., Werner, B. et al. (2018) Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C Phase II colorectal cancer clinical trial, Cancer Discov. 8:1270–1285 doi:10.1158/2159–8290. CD-17–0891

Luo, H., Zhao, Q., Wei, W. et al (2020) Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer, Science Translational Medicine 12: eaax7533 doi: 10.1126/ scitranslmed.aax7533

Kam, Y., Das, T., Tian, H. et al. (2015) Sweat but no gain: inhibiting proliferation of multidrug resistant cancer cells with 'ersatzdroges', International Journal of Cancer 136: E188–E196 doi:10.1002/ijc.29158

Merlo, L.M.F., Pepper, J.W., Reid, B.J. and Maley, C.C. (2006) Cancer as an evolutionary and ecological process, Nat. Rev. Cancer 6: 924–935 doi:10.1038/nrc2013

Gatenby, R.A., Brown, J. and Vincent, T. (2009) Lessons from applied ecology: cancer control using an evolutionary double bind, Cancer Res 69: 7499–7502 doi:10.1158/0008–5472.CAN-09–1354